¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Ellis type 1 glomerulonephritis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • poststreptococcal glomerulonephritis
    »ç½½¾Ë±Õ°¨¿°ÈÄÅ丮ÄáÆÏ¿°, ¿¬¼â±¸±Õ°¨¿°ÈĻ籸ü½Å¿°
  • rapidly progressive glomerulonephritis
    ±Þ¼ÓÁøÇàÅ丮ÄáÆÏ¿°, ±Þ¼ÓÁøÇà»ç±¸Ã¼½Å¿°
  • subacute diffuse glomerulonephritis
    ¾Æ±Þ¼º»êÀçÅ丮ÄáÆÏ¿°, ¾Æ±Þ¼º¹ü¹ß»ç±¸Ã¼½Å¿°
  • asthenic type
    ¹«·ÂüÇü
  • blood type
    Ç÷¾×Çü
  • Borrmann type
    º¸¸£¸¸Çü
  • Cowdry type A inclusion bodies
    Ä«¿ìµå¸®AÇüÆ÷ÇÔü, Ä«¿ìµå¸®AÇüºÀÀÔü
  • Cowdry type B inclusion bodies
    Ä«¿ìµå¸®BÇüÆ÷ÇÔü, Ä«¿ìµå¸®BÇüºÀÀÔü
  • delayed-type hypersensitivity
    Áö¿¬°ú¹Î(¼º)
  • disorganized type schizophrenia
    ºØ±«ÇüÁ¤½ÅºÐ¿­º´
  • extroverted feeling type
    ¿ÜÇâÀû°¨Á¤Çü
  • extroverted type
    ¿ÜÇâÇü
  • enteropathy-type T-cell lymphoma
    À庴ÁõÇüT¼¼Æ÷¸²ÇÁÁ¾
  • Golgi type I neuron
    ±äÃà»è½Å°æ¼¼Æ÷, °ñÁö1Çü½Å°æ¼¼Æ÷
  • Golgi type II neuron
    ªÀºÃà»è½Å°æ¼¼Æ÷, °ñÁö2Çü½Å°æ¼¼Æ÷
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • scirrhous type
    °æÈ­Çü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • abortive type
    ºÎÀüÇü
  • anovulatory type
    ¹«¹è¶õÇü
  • asthenic type
    ¹«·ÂüÇü
  • athletic type
    °ÇÀåÇü
  • precision type attachment
    Á¤¹ÐÇüºÎÂø
  • type specific antigen
    ÇüƯÀÌÇ׿ø
  • blood type
    Ç÷¾×Çü
  • bubble type vaporizer
    ±âÆ÷Çü±âÈ­±â
  • cellular type
    ¼¼Æ÷Çü
  • culture type
    Ç¥ÁرÕÁÖ, ±âÁØÁÖ
  • linear type constitution
    ¼±ÇüüÇü
  • swaged cast type crown
    ¾ÐÀÎÇü±Ý°ü
  • type culture
    Ç¥ÁرÕÁ¾
  • type culture collection
    Ç¥ÁرÕÁÖ¼ö·Ï
  • delayed-type hypersensitivity
    Áö¿¬°ú¹Î
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • B type virus particle
    BÇü ¹ÙÀÌ·¯½ºÀÔÀÚ.
  • B type virus particle
    BÇü ¹ÙÀÌ·¯½ºÀÔÀÚ.
  • C type particle
    CÇüÀÔÀÚ
  • C-type particle
    CÇü ÀÔÀÚ (·¹Æ®·Î¹ÙÀÌ·¯½ºÀÇ)
  • C-type virus particle
    CÇü ¹ÙÀÌ·¯½ºÀÔÀÚ.
  • Charcot-Marie type
    »þ¸£ÄÚ-¸¶¸®Çü.
  • Duchenne-Landouzy type
    µÚ½Ã¿£´À-¶õµÎ¿ìÁöÇü.
  • Gougerot-Ruiter type vasculitis
    ±¸Á¦·Î ·çÀÌÅÍ Çü Ç÷°ü¿°
  • L-type chnnels
    L-Çü Åë·Î(÷×ÖØ)
  • Lafora body type of myoclonus
    ¶óÆ÷¶ó üÇü ¸¶ÀÌ¿ÀŬ·Î´©½º.
  • Lutheran s type
    ·çÅ×¶õÇü.
  • Mobitz type I SA block
    ¸ðºñÃ÷ ¥°Çü µ¿¹æÂ÷´Ü.
  • Mobitz type II AV block
    ¸ðºñÃ÷ ¥±Çü ¹æ½ÇÂ÷´Ü.
  • Mobitz type II SA block
    ¸ðºñÃ÷ ¥±Çü µ¿¹æÂ÷´Ü.
  • Ogawa type
    ¿À°¡¿ÍÇü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • intercapillary glomerulonephritis
    ¸ð¼¼(Ç÷)°ü°£»ç±¸Ã¼½Å¿°.
  • membranous glomerulonephritis
    ¸·¼º»ç±¸ ü½Å¿°(¡­ÞêϹô÷ãìæú).
  • membranous glomerulonephritis
    ¸·¼º»ç±¸Ã¼½Å¿°(¡­Þêϳô÷ãìæú)
  • mesangiocapillary glomerulonephritis
    »ç±¸Ã¼°£Áú (¸Þ»êÁöÀ½)¸ð¼¼°ü¼º(Ù¾á¬Î·àõ) »ç±¸Ã¼½Å¿°
  • poststreptococcal(proliferative) glomerulonephritis
    ¿¬¼â»ó±¸±Õ°¨¿°ÈÄ(Áõ½Ä¼º) »ç±¸Ã¼½Å¿°(ææáðßÒϹжÊïæøý­(ñòãÖàõ) ÞêϹô÷ãìæú)
  • proliferative glomerulonephritis
    Áõ½Ä¼º »ç±¸Ã¼½Å¿°(ñòãÖàõ ÞêϹô÷ãìæú)
  • rapidly progressive (crescentic) glomerulonephritis
    ±Þ¼ÓÁøÇ༺»ç±¸Ã¼½Å¿°(ÐááÜòäú¼àõÞêϹô÷ãìæú)
  • rapidly progressive glomerulonephritis
    ±Þ¼ÓÁøÇ༺ »ç±¸Ã¼½Å¿°.
  • subacute diffuse glomerulonephritis
    ¾Æ±Þ¼º ¹ü¹ß¼º »ç±¸Ã¼½Å¿°(¡­ÛñÛ¡àõÞêϹ ô÷ãìæú).
  • subacute diffuse glomerulonephritis
    ¾Æ±Þ¼º ¹ü¹ß¼º »ç±¸Ã¼½Å¿°(¡­ÛñÛ¡àõÞêϹ ô÷ãìæú)
  • subacute glomerulonephritis
    ¾Æ±Þ¼º »ç±¸Ã¼½Å¿°(¡­ÞêϹô÷ãìæú).
  • subacute glomerulonephritis
    ¾Æ±Þ¼º »ç±¸Ã¼½Å¿°(¡­ÞêϹô÷ãìæú)
  • aberrant type
    ÀÌÇü(ì¶úþ)
  • abortive type
    ºÎÀüÇü(ÝÕîïúþ).
  • acute fulminating type
    ±Þ¼º Àü°ÝÇü.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Glomus type of arteriovenous anastomosis
    Å丮Çüµ¿Á¤¸Æ¿¬°á
    [¿¾ ¿ë¾î] ±¸Çüµ¿Á¤¸Æ¹®ÇÕ
  • Mixed type of artery
    È¥ÇÕÇüµ¿¸Æ
    [¿¾ ¿ë¾î] È¥ÇÕÇüµ¿¸Æ
  • Chief cell [Type I glomus cell]
    °ú¸³¼¼Æ÷
    [¿¾ ¿ë¾î] ÁÖ¼¼Æ÷
  • Pneumocyte type II
    °ú¸³ÇãÆÄ²Ê¸®¼¼Æ÷
    [¿¾ ¿ë¾î] ´ëÆóÆ÷¼¼Æ÷
  • Golgi type I neuron
    ±äÃà»è½Å°æ¼¼Æ÷
    [¿¾ ¿ë¾î] ÀåÃà»è´Ù±Ø½Å°æ¿ø
  • Supporting cell [Type II glomus cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁö¼¼Æ÷
  • Supporting cell [Type II glomus cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁö¼¼Æ÷(Á¦2Çü»ç±¸¼¼Æ÷)
  • Hypertrophic type
    ºñ´ëÇü
    [¿¾ ¿ë¾î] ºñ´ëÇü
  • Fibrous type of vein
    ¼¶À¯ÇüÁ¤¸Æ
    [¿¾ ¿ë¾î] ¼¶À¯ÇüÁ¤¸Æ
  • Golgi type II neuron
    ªÀºÃà»è½Å°æ¼¼Æ÷
    [¿¾ ¿ë¾î] ´ÜÃà»è´Ù±Ø½Å°æ¿ø
  • Pneumocyte type I
    È£ÈíÇãÆÄ²Ê¸®¼¼Æ÷
    [¿¾ ¿ë¾î] È£Èí»óÇǼ¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • type C virus
    CÇü(úþ) ¹ÙÀÌ·¯½º
  • type C RNA virus
    CÇü(úþ) RNA ¹ÙÀÌ·¯½º
  • type I error
    IÇü(úþ) ¿ÀÂ÷(è¦ó¬)
  • type II error
    IIÇü(úþ) ¿ÀÂ÷(è¦ó¬)
  • type I immunoglobulin
    IÇü(úþ) ¸é¿ª(Øóæ¹)±Û·ÎºÒ¸°
  • type II immunoglobulin
    IIÇü(úþ) ¸é¿ª(Øóæ¹)±Û·ÎºÒ¸°
  • type K immunoglobulin
    KÇü(úþ) ¸é¿ª(Øóæ¹) ±Û·ÎºÒ¸°
  • type L immunoglobulin
    LÇü(úþ) ¸é¿ª(Øóæ¹)±Û·ÎºÒ¸°
  • type-specific antigen
    ÇüƯÀÌ Ç׿ø(úþ÷åì¶ù÷ê«)
  • Watson-Crick-type DNA
    ¿Ó½¼-Å©¸¯Çü(úþ) DNA
  • wild-type
    ¾ß»ýÇü(å¯ßæúþ)
  • wild-type allele
    ¾ß»ýÇü(å¯ßæúþ) ´ë¸³(Óߨ¡)À¯ÀüÀÚ(ë¶îîí­)
  • wild-type gene
    ¾ß»ýÇü(å¯ßæúþ) À¯ÀüÀÚ(ë¶îîí­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ALL Acute Lymphocytic Leukemia
  ÇüÅÂÇÐÀû ºÐ·ù
    L1; Small, Homogenous(...
MEN Multiple Endocrine Neoplasia
  ; AD Trait
  1. MEN Type I(= Wermer Syndro...
NF Neuro-Fibromatosis
  = Von Recklinghausen's Disease
  NF 1; Neuro-Fibroma...
PFKL phosphofructokinase, liver type; 6-phosphofructo-2-kinase, liver type
PFKP phosphofructokinase, platelet type; 6-phosphofructo-2-kinase, platelet type
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CrGN Crescentic glomerulonephritis
DPGN Diffuse proliferative glomerulonephritis
EAG Experimental autoimmune glomerulonephritis
iMGN Idiopathic membranous glomerulonephritis
IgA GN IgA glomerulonephritis
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • defiant type
    ¹ÝÇ×Àû Çൿ À¯Çü
  • delayed-type hyperseneitivity
    Áö¿¬Çü °ú¹ÎÁõ
    °¨ÀÛµÈ T ¸²ÇÁ±¸¿¡ ÀÇÇÏ¿© Àü´ÞµÇ´Â °ú¹ÎÁõ. Ç×ü¿¡ ÀÇÇÏ¿© ¹ß»ýÇÏ´Â °ú¹ÎÁõÀÌ ¾Æ´Ï°í º¸Åë ¸²ÇÁ±¸¿Í macro
  • Diego blood type
    µð¿¡°í½Ä Ç÷¾×Çü
    Ç÷¾×ÇüÀÇ Çϳª. 1954³â º£³×¼ö¿¤¶óÀÇ µð¿¡°í°¡¿¡¼­ ½Å»ý¾Æ ¿ëÇ÷¼º Áúȯ ȯÀÚÀÇ ¾î¸Ó´Ï Ç÷û¿¡¼­ Ç×ü°¡, ¾Æ¹öÁö¿¡°Ô¼­´Â Ç׿øÀÌ ¹ß°ßµÇ¾ú´Ù. Di Ç×ü¿¡ ´ëÇØ ÀûÇ÷±¸°¡ ÀÀÁý ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â °ÍÀ» Di
  • distal step type
    ¿ø½É °è´ÜÇü
  • Dombrock blood type
    µ¼ºê·Ï½Ä Ç÷¾×Çü
    Ç÷¾×ÇüÀÇ Çϳª. »ç¶÷ÀÇ Ç÷±¸ °¡¿îµ¥ Ç×Do Ç×ü¿Í ÀÀÁý ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â Do
  • dorsolumbal type
    Èä¿äºÎ Çü, ¹èÃø ¿äºÎ Çü
  • dysplastic type
    ¹ßÀ° ºÎÀü ü°Ý
  • epidermoid type cell
    À¯Ç¥ÇÇ ¼¼Æ÷
  • ferm-type design
    ¾çÄ¡·ù ÇüÅÂÀÇ µðÀÚÀÎ
  • herpes simplex virus type 1
    Á¦1Çü ´Ü¼ø Æ÷Áø ¹ÙÀÌ·¯½º
  • herpes type I vaccine
    Á¦1Çü Æ÷Áø ¹é½Å
  • hinge type
    °æÃ¸Çü
    ÇϾǰñ ¿îµ¿.Áß ´Ü¼øÈ÷ °³±¸ ¶Ç´Â Æó±¸.¿îµ¿¸¸ ÇÏ´Â ÇüÅÂ.
  • HL-A type antigen
    ¿¡ÀÌÄ¡¿¤¿¡ÀÌ Ç׿ø
    »ç¶÷ÀÇ ÀûÇ÷±¸ ÀÌ¿ÜÀÇ ¸ðµç ¼¼Æ÷°¡ °¡Áö°í ÀÖ´Â Ç׿ø. »ç¶÷ ¹éÇ÷±¸ Ç׿øÀ̶ó°íµµ ÇÑ´Ù. H´Â »ç¶÷
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • hutchinson-type neuroblastoma
    ÇãÄ£½¼Çü ½Å°æ¸ð¼¼Æ÷Á¾
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
glomerulonephritis, IgA Chronic form of glomerulonephritis characterised by recurring haematuria with only slight proteinuria and by deposits of IgA immunoglobulin in the mesangial areas of the renal glomeruli. It usually occurs in young males.
(12 Dec 1998)
glomerulonephritis, membranoproliferative Chronic glomerulonephritis characterised histologically by proliferation of mesangial cells, increase in the mesangial matrix, and a thickening of the glomerular capillary walls. The wall thickening is sometimes said to be a result of the interposition of mesangial cytoplasm or matrix between the basement membrane and the endothelium of the capillary wall. It is often divided into types I and II, and sometimes III. Pathogenesis is not well understood, but some types are thought to involve the immune system, with the complement system, in particular, being implicated.
(12 Dec 1998)
glomerulonephritis, membranous A disease of the glomerulus manifested clinically by proteinuria, and sometimes by other features of the nephrotic syndrome. It is histologically characterised by deposits in the glomerular capillary wall between the epithelial cell and the basement membrane and a thickening of the membrane. Also characteristic are outward projections of the membrane between the epithelial deposits in the form of "spikes". There is some agreement that the deposits are antigen-antibody complexes.
(12 Dec 1998)
membranoproliferative glomerulonephritis <pathology> A kidney disorder which results in kidney dysfunction. Inflammation of the glomeruli result from an abnormal immune response and the deposition of antibodies within the kidney (glomerulus) ultrastructure.
Membranoproliferative glomerulonephritis has been divided into two different types in the basis of where the antibodies are deposited in the glomerulus. MPGN type I, the more common type, deposits antibodies in the subendothelial layer of the basement membrane, whereas type II deposits antibodies in the bottom layer of the basement membrane.
Symptoms include cloudy urine (pyuria), decreased urine output, swelling and hypertension. This disorder often results in end-stage renal disease.
Acronym: MPGN
(26 Mar 1998)
membranous glomerulonephritis <pathology> A kidney disease that occurs due to inflammation of the kidney glomerulus and its basement membrane.
The exact cause is unknown but it appears to be related to the deposition of immune complexes in the basement membrane leading to thickening of the capillary walls. This disorder is a common cause of nephrotic syndrome an is usually how the disease manifests.
Risk factors include primary renal disease, malaria, hepatitis B, lupus, syphilis, cancers and non-Hodgkin's lymphomas. Risks also include exposure to some medications such as gold compounds and penicillamine. Mercury, trimethadione and some skin-lightening creams have also been implicated.
Treatment includes systemic corticosteroids and immunosuppressive agents.
(26 Mar 1998)
mesangial proliferative glomerulonephritis <nephrology, pathology> Inflammation of the kidney glomerulus (blood filtering portion of the kidney) due to the abnormal deposition of IgM antibody in the mesangium layer of the glomerular capillary. A form of glomerulonephritis that appears to be caused by an abnormal immune response. This disorder generally manifests as nephrotic syndrome.
Symptoms include swelling, dark urine, weight gain, hypertension, anorexia and bloody urine.
Acronym: MPGN
(05 Jan 1998)
mesangiocapillary glomerulonephritis <nephrology, pathology> A kidney disorder which results in kidney dysfunction. Inflammation of the glomeruli result from an abnormal immune response and the deposition of antibodies within the kidney (glomerulus) ultrastructure.
Membranoproliferative glomerulonephritis has been divided into two different types in the basis of where the antibodies are deposited in the glomerulus. MPGN type I, the more common type, deposits antibodies in the subendothelial layer of the basement membrane, whereas type II deposits antibodies in the bottom layer of the basement membrane.
Symptoms include cloudy urine (pyuria), decreased urine output, swelling and hypertension. This disorder often results in end-stage renal disease.
(27 Sep 1997)
chronic glomerulonephritis Glomerulonephritis that presents with persisting proteinuria, chronic renal failure, and hypertension, of insidious onset or as a late sequel of acute glomerulonephritis; the kidneys are symmetrically contracted and granular, with scarring and loss of glomeruli and the presence of tubular atrophy and interstitial fibrosis.
Synonym: chronic nephritis.
(05 Mar 2000)
crescentic glomerulonephritis <nephrology, pathology> A relatively uncommon (affecting 1 out of 10,000 people) form of acute glomerulonephritis that results in damage within the glomerulus of the kidney. There is rapid loss of kidney function with the formation of crescents on microscopic analysis (kidney biopsy). This disorder may result in acute glomerulonephritis or nephrotic syndrome, but ultimately results in renal failure and end-stage renal disease.
Symptoms include smoky coloured urine (pyuria), decreased urine output, swelling and hypertension. Any conditions which can cause a vasculitis increase the risk of this disorder. Some examples include lupus, Goodpasture's syndrome, Henoch-Schonlein purpura, IgA nephropathy, membranoproliferative glomerulonephritis, anti-glomerular basement membrane antibody disease, history for malignant tumours and exposure to hydrocarbon solvents.
(27 Sep 1997)
proliferative glomerulonephritis Glomerulonephritis with hypercellularity of glomeruli due to proliferation of endothelial or mesangial cells, occurring in acute glomerulonephritis and membranoproliferative glomerulonephritis.
(05 Mar 2000)
segmental glomerulonephritis Glomerulonephritis affecting only part of a glomerulus or glomeruli.
Synonym: local glomerulonephritis.
(05 Mar 2000)
hypocomplementemic glomerulonephritis <pathology> A kidney disorder which results in kidney dysfunction. Inflammation of the glomeruli result from an abnormal immune response and the deposition of antibodies within the kidney (glomerulus) ultrastructure.
Membranoproliferative glomerulonephritis has been divided into two different types in the basis of where the antibodies are deposited in the glomerulus. MPGN type I, the more common type, deposits antibodies in the subendothelial layer of the basement membrane, whereas type II deposits antibodies in the bottom layer of the basement membrane.
Symptoms include cloudy urine (pyuria), decreased urine output, swelling and hypertension. This disorder often results in end-stage renal disease.
Acronym: MPGN
(26 Mar 1998)
necrotising glomerulonephritis <pathology> A relatively uncommon (affecting 1 out of 10,000 people) form of acute glomerulonephritis that results in damage within the glomerulus of the kidney. There is rapid loss of kidney function with the formation of crescents on microscopic analysis (kidney biopsy). This disorder may result in acute glomerulonephritis or nephrotic syndrome, but ultimately results in renal failure and end-stage renal disease.
Symptoms include smoky coloured urine (pyuria), decreased urine output, swelling and hypertension. Any conditions which can cause a vasculitis increase the risk of this disorder. Some examples include lupus, Goodpasture's syndrome, Henoch-Schonlein purpura, IgA nephropathy, membranoproliferative glomerulonephritis, anti-glomerular basement membrane antibody disease, history for malignant tumours and exposure to hydrocarbon solvents.
(27 Sep 1997)
subacute glomerulonephritis Undesirable term for glomerulonephritis with proteinuria, haematuria and azotemia persisting for many weeks; renal changes are variable, including those of rapidly progressive and membranoproliferative glomerulonephritis.
Synonym: subacute nephritis.
(05 Mar 2000)
diffuse glomerulonephritis Glomerulonephritis affecting most of the renal glomeruli; it may lead to azotemia.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • italic type
    (ÀÎ)ÀÌÅÚ¸¯Ã¼;»çü
  • moon type
    (¸ÍÀοëÀÇ)¹®½Ä¼±ÀÚ
  • repulsive(-type) maglev
    ¹Ý¹ß½Ä Àڱ⠺λó(Â÷ü¸¦ ¶ß°ÔÇϱâ À§ÇØ ÀüÀÚ¼®ÀÇ ¹Ý¹ß·ÂÀ» ÀÌ¿ë)
  • type
    Çü;À¯Çü;¾ç½Ä;ÀüÇü;°ßº»;Ç¥;ȰÀÚ;Ç÷¾×Çü;in ~ ȰÀڷΠ§(Â¥¼­);set ~ Á¶ÆÇÇÏ´Ù
  • type
    ŸÀÌÇÁ¶óÀÌÅÍ·Î Âï´Ù;(Ç÷¾×)ÇüÀ» °Ë»çÇÏ´Ù;»ó¡ÇÏ´Ù;...ÀÇ ÀüÇüÀÌ µÇ´Ù
  • type cast
    (±ØÁß Àι°ÀÇ ½ÅÀå,¸ñ¼Ò¸® µûÀ§¿¡ ¸Â´Â) ¹è¿ì¸¦ ¹è¿ªÇÏ´Ù
  • type founder
    ȰÀÚ ÁÖÁ¶°ø(¾÷ÀÚ)
  • type metal
    ȰÀÚ ÇÕ±Ý
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á